At AAPS with CritiTech Particle Engineering Solutions
Matthew McClorey, President of CritiTech Particle Engineering Solutions, shares his insights at AAPS.
At a recent American Association of Pharmaceutical Scientists (AAPS) convention, BioPharm International sat down with Matthew McClorey, President of CritiTech Particle Engineering Solutions.
Learn more about:
- What makes CritiTech unique in the CDMO market.
- What you can expect from working with CritiTech.
- The company’s ability to formulate direct-to-site treatments from previously systemically delivered drugs with the patented Purcision platform.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Recent Videos
Related Content
